v3.26.1
Revenue (Tables)
6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of amounts were recognized within revenue

Three Months Ended June 30, 

Six Months Ended June 30, 

(In thousands)

2026

2025

2026

2025

Viatris collaboration agreement – Amounts receivable from Viatris

$

20,731

$

18,695

$

38,430

$

34,083

Licensing revenue – China Region regulatory approval milestone

7,500

7,500

Total

$

20,731

$

26,195

$

38,430

$

41,583

 

Schedule of implied share of total net sales

Three Months Ended June 30, 

Six Months Ended June 30, 

(In thousands)

  ​

2026

  ​

2025

  ​ ​ ​

2026

  ​

2025

YUPELRI net sales (Theravance Biopharma implied 35%)

$

24,733

$

23,216

$

46,584

$

43,636